Overview

Efficacy and Tolerability Study of Two Dose Regimens of CTP-543 in Adults With Alopecia Areata

Status:
Completed
Trial end date:
2019-11-21
Target enrollment:
Participant gender:
Summary
A randomized, multi-center study to evaluate the efficacy and tolerability of once-daily versus twice daily dosing of CTP-543, in adult patients with chronic, moderate to severe alopecia areata
Phase:
Phase 2
Details
Lead Sponsor:
Concert Pharmaceuticals